

Calithera Biosciences

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 15-Dec-2014

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)

ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 6

Product Portfolio Drug Pipeline Detail..... 10

 Phase 1 Clinical..... 11

 Discovery..... 14

[Return to Table of Contents](#)

Calithera Biosciences

COMPANY OVERVIEW

Company Name	Calithera Biosciences
Parent Company Name	Calithera Biosciences
Website	http://www.calithera.com/
Country	US
Number of Drugs in Active Development	3
Number of Inactive Drugs	1
Number of Patents as Owner	2
Number of Patents as Third Party	0
Number of Deals	3
Key Indications	Cancer,Advanced solid tumor,Hematological neoplasm,Breast tumor,Colorectal tumor,Endocrine tumor,Hodgkins disease,Immune disorder,Leukemia,Lung tumor,Lymphoblastic leukemia,Lymphoma,Multiple myeloma,Neurological disease,Renal tumor
Key Target-based Actions	Arginase inhibitor,Mcl-1 differentiation protein inhibitor,Mitochondrial kidney glutaminase inhibitor
Key Technologies	Small molecule therapeutic,Oral formulation

COMPANY PROFILE

SUMMARY

Calithera Biosciences, founded in 2010 with technology licensed from the University of California, San Francisco, is focused on the development of cancer therapies based on the activation of caspase and other enzymes.

FINANCIAL

In October 2014, the company priced its initial public offering of 8 million shares of common stock at \$10 per share. The underwriters were granted a 30-day option to purchase up to 1.2 million additional shares of common stock. At that time, the common stock of the company began trading on the NASDAQ global select market, under the ticker symbol "CALA".

In October 2013, Calithera raised \$35 million in series D financing.

In July 2010, Calithera raised \$40 million in a series A financing.

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	3	1	4
Hematological disease	1	0	1

[Return to Table of Contents](#)

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 1 Clinical	1
Discovery	2
No Development Reported	1

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Early Research/Development	0	0	1	0	1
Drug - Development/Commercialization License	0	0	2	0	2

[Return to Table of Contents](#)

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Neoplasm	3	3
Hematological disease	2	2
Respiratory disease	1	1
Immune disorder	1	1
Gynecology and obstetrics	1	1
Genitourinary disease	1	1
Endocrine disease	1	1
Gastrointestinal disease	1	1

Trials by Phase

Phase	Ongoing	All
Phase 1	3	3

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Endocrine disease	1	0	1
Gastrointestinal disease	1	0	1
Genitourinary disease	1	0	1
Hematological disease	1	0	1
Immune disorder	2	0	2
Neoplasm	2	0	2
Neurological disease	1	0	1
Respiratory disease	1	0	1

[Return to Table of Contents](#)



Gynecology and obstetrics	1	0	1
---------------------------	---	---	---

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

CB-839

CB-839 SNAPSHOT

Drug Name	CB-839
Key Synonyms	
Originator Company	Calithera Biosciences
Active Companies	Sanford-Burnham Medical Research Institute;Calithera Biosciences
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Hematological neoplasm;Advanced solid tumor
Target-based Actions	
Other Actions	Glutaminase inhibitor;Anticancer
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	05-Dec-2014

CB-839 DEVELOPMENT PROFILE

SUMMARY

Calithera, in collaboration with Sanford-Burnham is developing CB-839, a lead from a program of glutaminase inhibitors for the potential oral treatment of cancer,. In February 2014, three phase I trials were initiated in patients with advanced solid tumors and hematological cancers including advanced multiple myeloma and non-Hodgkin's lymphoma. In September 2014, two phase Ib trials were planned to begin in late 2014 . In November 2014, the company was planning to initiate phase II trials in late 2015 or in early 2016.

CB-839 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Calithera Biosciences	Advanced solid tumor	US	Phase 1 Clinical	24-Feb-2014
Calithera Biosciences	Hematological neoplasm	US	Phase 1 Clinical	24-Feb-2014
Sanford-Burnham Medical Research Institute	Advanced solid tumor	US	Phase 1 Clinical	24-Feb-2014
Sanford-Burnham Medical Research Institute	Hematological neoplasm	US	Phase 1 Clinical	24-Feb-2014

[Return to Table of Contents](#)



CB-839 DRUG NAMES

Names	Type
glutaminase inhibitors (oral, cancer), Calithera Bioscience	
CB-839	Research Code

CB-839 CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Mesothelioma											
0	0	0	0	0	0	1	1	0	0	1	1
Acute lymphoblastic leukemia											
0	0	0	0	0	0	1	1	0	0	1	1
Non-small-cell lung cancer											
0	0	0	0	0	0	1	1	0	0	1	1
Hematological neoplasm											
0	0	0	0	0	0	1	1	0	0	1	1
Gastrointestinal stromal tumor											
0	0	0	0	0	0	1	1	0	0	1	1
Acute myelogenous leukemia											
0	0	0	0	0	0	1	1	0	0	1	1
Renal cell carcinoma											
0	0	0	0	0	0	1	1	0	0	1	1
Advanced solid tumor											
0	0	0	0	0	0	1	1	0	0	1	1
Multiple myeloma											
0	0	0	0	0	0	1	1	0	0	1	1
Non-Hodgkin lymphoma											
0	0	0	0	0	0	1	1	0	0	1	1

[Return to Table of Contents](#)

Breast tumor											
0	0	0	0	0	0	1	1	0	0	1	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	3	3	0	0	3	3

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

CB-839 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




[Return to Table of Contents](#)

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Calithera Biosciences	0	0	1	0	1
Sanford-Burnham Medical Research Institute	1	0	0	0	1

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Early Research/Development	1	0	1

[Return to Table of Contents](#)

Mcl-1 inhibitors (cancer), Calithera Biosciences

Mcl-1 inhibitors (cancer), Calithera Biosciences SNAPSHOT

Drug Name	Mcl-1 inhibitors (cancer), Calithera Biosciences
Key Synonyms	
Originator Company	Calithera Biosciences
Active Companies	Calithera Biosciences
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Mcl-1 differentiation protein inhibitor
Other Actions	Anticancer;Apoptosis stimulator
Technologies	Small molecule therapeutic
Last Change Date	02-Nov-2013

Mcl-1 inhibitors (cancer), Calithera Biosciences DEVELOPMENT PROFILE

SUMMARY

Calithera Biosciences is investigating a program of small molecule selective Mcl-1 inhibitors for the potential treatment of cancer. Preclinical studies were ongoing by October 2013.

Mcl-1 inhibitors (cancer), Calithera Biosciences DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Calithera Biosciences	Cancer	US	Discovery	29-Oct-2013

Mcl-1 inhibitors (cancer), Calithera Biosciences DRUG NAMES

Names	Type
Mcl-1 inhibitors (cancer), Calithera Biosciences	

[Return to Table of Contents](#)

arginase inhibitors (cancer), Calithera Biosciences

arginase inhibitors (cancer), Calithera Biosciences SNAPSHOT

Drug Name	arginase inhibitors (cancer), Calithera Biosciences
Key Synonyms	
Originator Company	Calithera Biosciences
Active Companies	Calithera Biosciences
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Arginase inhibitor
Other Actions	Anticancer
Technologies	Small molecule therapeutic
Last Change Date	18-Nov-2014

arginase inhibitors (cancer), Calithera Biosciences DEVELOPMENT PROFILE

SUMMARY

Calithera Biosciences is investigating arginase inhibitors for the potential treatment of cancer ,. In September 2014, the company planned to file an IND application with the US FDA by the end of 2015 to initiate a phase I trial in 2016.

arginase inhibitors (cancer), Calithera Biosciences DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Calithera Biosciences	Cancer	US	Discovery	30-Sep-2014

arginase inhibitors (cancer), Calithera Biosciences DRUG NAMES

Names	Type
arginase inhibitors (cancer), Calithera Biosciences	

[Return to Table of Contents](#)



This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

